PipelineReview.com4h
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease
The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of ...
EDAP TMS S.A.: EDAP Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology
EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial sponsored ...
EDAP Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology
EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first ...